Qiuxia Chen
Research Subjects
Qiuxia Chen has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Ai-Ming Yu
Department of Biochemistry and Molecular Medicine, UC Davis School of Medicine, Sacramento, CA 95817, USA
3 shared publications Su Zeng
3 shared publications- Balasubrahmanyam Addepalli
University of Cincinnati
2 shared publications Wei-Peng Wang
2 shared publicationsXuemin Cheng
HitGen Inc. , Shuangliu District , Chengdu , China
2 shared publications- Aimin Yu
Department of Chemistry and Biotechnology, Swinburne University of Technology, Hawthorn, VIC 3122, Australia
1 shared publication
Latest Publications
- 10 September 2022
- Published by Springer Nature
- Vol. 2541, 155-164
DEL Selections Against a Soluble Protein Target
Affinity-based DNA-encoded library (DEL) selection is considered a powerful tool for small molecule drug discovery. Such selections are a multi-round process that involves incubation of a target protein with the DEL, capture of the protein and associated DEL compounds on a solid support, separation of bound molecules from the bulk DEL that is unbound, and recovery of bound DEL molecules. Each step is of great importance in order to achieve successful selections. Here we describe the selection process against a soluble target protein in both the immobilized and in-solution modes. Key words DEL Selection Immobilization mode In-solution mode qPCR SDS-PAGE Hit discovery
- 10 September 2022
- Published by Springer Nature
- Vol. 2541, 155-164
DEL Selections Against a Soluble Protein Target
Affinity-based DNA-encoded library (DEL) selection is considered a powerful tool for small molecule drug discovery. Such selections are a multi-round process that involves incubation of a target protein with the DEL, capture of the protein and associated DEL compounds on a solid support, separation of bound molecules from the bulk DEL that is unbound, and recovery of bound DEL molecules. Each step is of great importance in order to achieve successful selections. Here we describe the selection process against a soluble target protein in both the immobilized and in-solution modes. Key words DEL Selection Immobilization mode In-solution mode qPCR SDS-PAGE Hit discovery
- 10 September 2022
- Published by Springer Nature
- Vol. 2541, 143-154
Target Protein Design and Preselection Analysis
DNA-encoded library (DEL) technology utilizes affinity-based selection methods to screen chemical libraries. DEL technology possesses some unique features compared to other small molecule screening technologies, such as the use of DNA identification tags and use of target protein immobilization in the standard library screening process. Therefore, it is of great importance to ensure the target protein is properly designed for DEL selections, that the protein is of high quality, and that ligand binding sites are accessible under DEL selection conditions. Here we describe general considerations for target protein design and expression and experiments that are conducted before initiating selections to assess protein quality and validate methods that will be used for the DEL selection. Key words Target protein design Selection methods Protein immobilization Protein stability Immobilized activity Affinity tag
- 10 September 2022
- Published by Springer Nature
- Vol. 2541, 143-154
Target Protein Design and Preselection Analysis
DNA-encoded library (DEL) technology utilizes affinity-based selection methods to screen chemical libraries. DEL technology possesses some unique features compared to other small molecule screening technologies, such as the use of DNA identification tags and use of target protein immobilization in the standard library screening process. Therefore, it is of great importance to ensure the target protein is properly designed for DEL selections, that the protein is of high quality, and that ligand binding sites are accessible under DEL selection conditions. Here we describe general considerations for target protein design and expression and experiments that are conducted before initiating selections to assess protein quality and validate methods that will be used for the DEL selection. Key words Target protein design Selection methods Protein immobilization Protein stability Immobilized activity Affinity tag
- Open Access
- 26 August 2022
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 13  (11) , 1341-1349
PAC-FragmentDEL – photoactivated covalent capture of DNA-encoded fragments for hit discovery
Fragments bind weakly to specific sites on proteins. A library where a photoactivatable group is linked to DNA encoded fragments covalently links the protein to binding fragments whose identity is determined by PCR and sequencing.
- 26 August 2022
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 13  (11) , 1341-1349
Open AccessPAC-FragmentDEL – photoactivated covalent capture of DNA-encoded fragments for hit discovery
Fragments bind weakly to specific sites on proteins. A library where a photoactivatable group is linked to DNA encoded fragments covalently links the protein to binding fragments whose identity is determined by PCR and sequencing.
- Open Access
- 14 March 2022
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 50  (12) , e67
Expanding the DNA-encoded library toolbox: identifying small molecules targeting RNA
DNA-encoded library (DEL) technology is a powerful tool for small molecule identification in drug discovery, yet the reported DEL selection strategies were applied primarily on protein targets in either purified form or in cellular context. To expand the application of this technology, we employed DEL selection on an RNA target HIV-1 TAR (trans-acting responsive region), but found that the majority of signals were resulted from false positive DNA–RNA binding. We thus developed an optimized selection strategy utilizing RNA patches and competitive elution to minimize unwanted DNA binding, followed by k-mer analysis and motif search to differentiate false positive signal. This optimized strategy resulted in a very clean background in a DEL selection against Escherichia coli FMN Riboswitch, and the enriched compounds were determined with double digit nanomolar binding affinity, as well as similar potency in functional FMN competition assay. These results demonstrated the feasibility of small molecule identification against RNA targets using DEL selection. The developed experimental and computational strategy provided a promising opportunity for RNA ligand screening and expanded the application of DEL selection to a much wider context in drug discovery.
- 14 March 2022
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 50  (12) , e67
Open AccessExpanding the DNA-encoded library toolbox: identifying small molecules targeting RNA
DNA-encoded library (DEL) technology is a powerful tool for small molecule identification in drug discovery, yet the reported DEL selection strategies were applied primarily on protein targets in either purified form or in cellular context. To expand the application of this technology, we employed DEL selection on an RNA target HIV-1 TAR (trans-acting responsive region), but found that the majority of signals were resulted from false positive DNA–RNA binding. We thus developed an optimized selection strategy utilizing RNA patches and competitive elution to minimize unwanted DNA binding, followed by k-mer analysis and motif search to differentiate false positive signal. This optimized strategy resulted in a very clean background in a DEL selection against Escherichia coli FMN Riboswitch, and the enriched compounds were determined with double digit nanomolar binding affinity, as well as similar potency in functional FMN competition assay. These results demonstrated the feasibility of small molecule identification against RNA targets using DEL selection. The developed experimental and computational strategy provided a promising opportunity for RNA ligand screening and expanded the application of DEL selection to a much wider context in drug discovery.
- 1 December 2020
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 533  (2) , 249-255
A method for estimating binding affinity from primary DEL selection data
- 1 December 2020
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 533  (2) , 249-255
A method for estimating binding affinity from primary DEL selection data
- Open Access
- 1 June 2020
- Published by Elsevier in SLAS Discovery
- Vol. 25  (5) , 523-529
Exploring the Lower Limit of Individual DNA-Encoded Library Molecules in Selection
- 1 June 2020
- Published by Elsevier in SLAS Discovery
- Vol. 25  (5) , 523-529
Open AccessExploring the Lower Limit of Individual DNA-Encoded Library Molecules in Selection
- 1 December 2019
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- Vol. 26, 93-100
Accelerating Fine-Grained Spatial-Textual Trajectory Similarity Joins with GPGPUs
The increasing volume of spatial-textual data generated from check-ins and reviews facilitates many practical applications. In these applications, similarity joins are the basic operation which further supports a wide range of similarity queries. However, this compute-intensive join operation calls for more efficient and effective algorithm to support real-time queries. Exploiting general purpose GPUs (GPGPUs) is one natural solution. Nevertheless, existing join algorithms utilizing GPGPU lack considerations on unique features of spatial-textual trajectories, especially the textual domain, thus resulting in poor performance. In this paper, we first propose a baseline spatial-textual trajectory similarity join algorithm, which is essentially based on a traditional algorithm for relational joins on GPGPUs. Then, by analyzing the bottleneck of this baseline, we further develop a fine-grained join algorithm which consists of memory access techniques and optimizations. We propose a strategy of flip to ensure coalesced memory accesses, and a batch scheduler for dividing the whole task into batches to fit the global memory while alleviating imbalanced throughput. Extensive experiments have been conducted over real-life datasets and the results show that our fine-grained algorithm performs the best and reduces the latency effectively.
- 1 December 2019
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- Vol. 26, 93-100
Accelerating Fine-Grained Spatial-Textual Trajectory Similarity Joins with GPGPUs
The increasing volume of spatial-textual data generated from check-ins and reviews facilitates many practical applications. In these applications, similarity joins are the basic operation which further supports a wide range of similarity queries. However, this compute-intensive join operation calls for more efficient and effective algorithm to support real-time queries. Exploiting general purpose GPUs (GPGPUs) is one natural solution. Nevertheless, existing join algorithms utilizing GPGPU lack considerations on unique features of spatial-textual trajectories, especially the textual domain, thus resulting in poor performance. In this paper, we first propose a baseline spatial-textual trajectory similarity join algorithm, which is essentially based on a traditional algorithm for relational joins on GPGPUs. Then, by analyzing the bottleneck of this baseline, we further develop a fine-grained join algorithm which consists of memory access techniques and optimizations. We propose a strategy of flip to ensure coalesced memory accesses, and a batch scheduler for dividing the whole task into batches to fit the global memory while alleviating imbalanced throughput. Extensive experiments have been conducted over real-life datasets and the results show that our fine-grained algorithm performs the best and reduces the latency effectively.
- Open Access
- 1 August 2015
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 354  (2) , 131-141
Bioengineering Novel Chimeric microRNA-34a for Prodrug Cancer Therapy: High-Yield Expression and Purification, and Structural and Functional Characterization
Development of anticancer treatments based on microRNA (miRNA/miR) such as miR-34a replacement therapy is limited to the use of synthetic RNAs with artificial modifications. Herein, we present a new approach to a high-yield and large-scale biosynthesis, in Escherichia coli using transfer RNA (tRNA) scaffold, of chimeric miR-34a agent, which may act as a prodrug for anticancer therapy. The recombinant tRNA fusion pre–miR-34a (tRNA/mir-34a) was quickly purified to a high degree of homogeneity (>98%) using anion-exchange fast protein liquid chromatography, whose primary sequence and post-transcriptional modifications were directly characterized by mass spectrometric analyses. Chimeric tRNA/mir-34a showed a favorable cellular stability while it was degradable by several ribonucleases. Deep sequencing and quantitative real-time polymerase chain reaction studies revealed that tRNA-carried pre–miR-34a was precisely processed to mature miR-34a within human carcinoma cells, and the same tRNA fragments were produced from tRNA/mir-34a and the control tRNA scaffold (tRNA/MSA). Consequently, tRNA/mir-34a inhibited the proliferation of various types of human carcinoma cells in a dose-dependent manner and to a much greater degree than the control tRNA/MSA, which was mechanistically attributable to the reduction of miR-34a target genes. Furthermore, tRNA/mir-34a significantly suppressed the growth of human non–small-cell lung cancer A549 and hepatocarcinoma HepG2 xenograft tumors in mice, compared with the same dose of tRNA/MSA. In addition, recombinant tRNA/mir-34a had no or minimal effect on blood chemistry and interleukin-6 level in mouse models, suggesting that recombinant RNAs were well tolerated. These findings provoke a conversation on producing biologic miRNAs to perform miRNA actions, and point toward a new direction in developing miRNA-based therapies.
- 1 August 2015
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 354  (2) , 131-141
Open AccessBioengineering Novel Chimeric microRNA-34a for Prodrug Cancer Therapy: High-Yield Expression and Purification, and Structural and Functional Characterization
Development of anticancer treatments based on microRNA (miRNA/miR) such as miR-34a replacement therapy is limited to the use of synthetic RNAs with artificial modifications. Herein, we present a new approach to a high-yield and large-scale biosynthesis, in Escherichia coli using transfer RNA (tRNA) scaffold, of chimeric miR-34a agent, which may act as a prodrug for anticancer therapy. The recombinant tRNA fusion pre–miR-34a (tRNA/mir-34a) was quickly purified to a high degree of homogeneity (>98%) using anion-exchange fast protein liquid chromatography, whose primary sequence and post-transcriptional modifications were directly characterized by mass spectrometric analyses. Chimeric tRNA/mir-34a showed a favorable cellular stability while it was degradable by several ribonucleases. Deep sequencing and quantitative real-time polymerase chain reaction studies revealed that tRNA-carried pre–miR-34a was precisely processed to mature miR-34a within human carcinoma cells, and the same tRNA fragments were produced from tRNA/mir-34a and the control tRNA scaffold (tRNA/MSA). Consequently, tRNA/mir-34a inhibited the proliferation of various types of human carcinoma cells in a dose-dependent manner and to a much greater degree than the control tRNA/MSA, which was mechanistically attributable to the reduction of miR-34a target genes. Furthermore, tRNA/mir-34a significantly suppressed the growth of human non–small-cell lung cancer A549 and hepatocarcinoma HepG2 xenograft tumors in mice, compared with the same dose of tRNA/MSA. In addition, recombinant tRNA/mir-34a had no or minimal effect on blood chemistry and interleukin-6 level in mouse models, suggesting that recombinant RNAs were well tolerated. These findings provoke a conversation on producing biologic miRNAs to perform miRNA actions, and point toward a new direction in developing miRNA-based therapies.
- 1 July 2015
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 43  (7) , 1129-1136
Chimeric MicroRNA-1291 Biosynthesized Efficiently in Escherichia coli Is Effective to Reduce Target Gene Expression in Human Carcinoma Cells and Improve Chemosensitivity
In contrast to the growing interests in studying noncoding RNAs (ncRNAs) such as microRNA (miRNA or miR) pharmacoepigenetics, there is a lack of efficient means to cost effectively produce large quantities of natural miRNA agents. Our recent efforts led to a successful production of chimeric pre-miR-27b in bacteria using a transfer RNA (tRNA)–based recombinant RNA technology, but at very low expression levels. Herein, we present a high-yield expression of chimeric pre-miR-1291 in common Escherichia coli strains using the same tRNA scaffold. The tRNA fusion pre-miR-1291 (tRNA/mir-1291) was then purified to high homogeneity using affinity chromatography, whose primary sequence and post-transcriptional modifications were directly characterized by mass spectrometric analyses. Chimeric tRNA/mir-1291 was readily processed to mature miR-1291 in human carcinoma MCF-7 and PANC-1 cells. Consequently, recombinant tRNA/mir-1291 reduced the protein levels of miR-1291 target genes, including ABCC1, FOXA2, and MeCP2, as compared with cells transfected with the same doses of control methionyl-tRNA scaffold with a sephadex aptamer (tRNA/MSA). In addition, tRNA-carried pre-miR-1291 suppressed the growth of MCF-7 and PANC-1 cells in a dose-dependent manner, and significantly enhanced the sensitivity of ABCC1-overexpressing PANC-1 cells to doxorubicin. These results indicate that recombinant miR-1291 agent is effective in the modulation of target gene expression and chemosensitivity, which may provide insights into high-yield bioengineering of new ncRNA agents for pharmacoepigenetics research.
- 1 July 2015
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 43  (7) , 1129-1136
Chimeric MicroRNA-1291 Biosynthesized Efficiently in Escherichia coli Is Effective to Reduce Target Gene Expression in Human Carcinoma Cells and Improve Chemosensitivity
In contrast to the growing interests in studying noncoding RNAs (ncRNAs) such as microRNA (miRNA or miR) pharmacoepigenetics, there is a lack of efficient means to cost effectively produce large quantities of natural miRNA agents. Our recent efforts led to a successful production of chimeric pre-miR-27b in bacteria using a transfer RNA (tRNA)–based recombinant RNA technology, but at very low expression levels. Herein, we present a high-yield expression of chimeric pre-miR-1291 in common Escherichia coli strains using the same tRNA scaffold. The tRNA fusion pre-miR-1291 (tRNA/mir-1291) was then purified to high homogeneity using affinity chromatography, whose primary sequence and post-transcriptional modifications were directly characterized by mass spectrometric analyses. Chimeric tRNA/mir-1291 was readily processed to mature miR-1291 in human carcinoma MCF-7 and PANC-1 cells. Consequently, recombinant tRNA/mir-1291 reduced the protein levels of miR-1291 target genes, including ABCC1, FOXA2, and MeCP2, as compared with cells transfected with the same doses of control methionyl-tRNA scaffold with a sephadex aptamer (tRNA/MSA). In addition, tRNA-carried pre-miR-1291 suppressed the growth of MCF-7 and PANC-1 cells in a dose-dependent manner, and significantly enhanced the sensitivity of ABCC1-overexpressing PANC-1 cells to doxorubicin. These results indicate that recombinant miR-1291 agent is effective in the modulation of target gene expression and chemosensitivity, which may provide insights into high-yield bioengineering of new ncRNA agents for pharmacoepigenetics research.
- Open Access
- 23 March 2015
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 43  (7) , 3857-3869
A general approach to high-yield biosynthesis of chimeric RNAs bearing various types of functional small RNAs for broad applications
RNA research and therapy relies primarily on synthetic RNAs. We employed recombinant RNA technology toward large-scale production of pre-miRNA agents in bacteria, but found the majority of target RNAs were not or negligibly expressed. We thus developed a novel strategy to achieve consistent high-yield biosynthesis of chimeric RNAs carrying various small RNAs (e.g. miRNAs, siRNAs and RNA aptamers), which was based upon an optimal noncoding RNA scaffold (OnRS) derived from tRNA fusion pre-miR-34a (tRNA/mir-34a). Multi-milligrams of chimeric RNAs (e.g. OnRS/miR-124, OnRS/GFP-siRNA, OnRS/Neg (scrambled RNA) and OnRS/MGA (malachite green aptamer)) were readily obtained from 1 l bacterial culture. Deep sequencing analyses revealed that mature miR-124 and target GFP-siRNA were selectively released from chimeric RNAs in human cells. Consequently, OnRS/miR-124 was active in suppressing miR-124 target gene expression and controlling cellular processes, and OnRS/GFP-siRNA was effective in knocking down GFP mRNA levels and fluorescent intensity in ES-2/GFP cells and GFP-transgenic mice. Furthermore, the OnRS/MGA sensor offered a specific strong fluorescence upon binding MG, which was utilized as label-free substrate to accurately determine serum RNase activities in pancreatic cancer patients. These results demonstrate that OnRS-based bioengineering is a common, robust and versatile strategy to assemble various types of small RNAs for broad applications.
- 23 March 2015
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 43  (7) , 3857-3869
Open AccessA general approach to high-yield biosynthesis of chimeric RNAs bearing various types of functional small RNAs for broad applications
RNA research and therapy relies primarily on synthetic RNAs. We employed recombinant RNA technology toward large-scale production of pre-miRNA agents in bacteria, but found the majority of target RNAs were not or negligibly expressed. We thus developed a novel strategy to achieve consistent high-yield biosynthesis of chimeric RNAs carrying various small RNAs (e.g. miRNAs, siRNAs and RNA aptamers), which was based upon an optimal noncoding RNA scaffold (OnRS) derived from tRNA fusion pre-miR-34a (tRNA/mir-34a). Multi-milligrams of chimeric RNAs (e.g. OnRS/miR-124, OnRS/GFP-siRNA, OnRS/Neg (scrambled RNA) and OnRS/MGA (malachite green aptamer)) were readily obtained from 1 l bacterial culture. Deep sequencing analyses revealed that mature miR-124 and target GFP-siRNA were selectively released from chimeric RNAs in human cells. Consequently, OnRS/miR-124 was active in suppressing miR-124 target gene expression and controlling cellular processes, and OnRS/GFP-siRNA was effective in knocking down GFP mRNA levels and fluorescent intensity in ES-2/GFP cells and GFP-transgenic mice. Furthermore, the OnRS/MGA sensor offered a specific strong fluorescence upon binding MG, which was utilized as label-free substrate to accurately determine serum RNase activities in pancreatic cancer patients. These results demonstrate that OnRS-based bioengineering is a common, robust and versatile strategy to assemble various types of small RNAs for broad applications.